Rationale Objective Study Schema Treatment Plan Eligibility Criteria Rationale Follow Up
A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia | Trials | Full Text
Ibrutinib in Combination with Rituximab or Lenalidomide/Rituximab for Untreated FL | Research To Practice
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
RESONATE-2 - Study Design | IMBRUVICA® (ibrutinib) HCP
Cancers | Free Full-Text | First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL | NEJM
A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma | Haematologica
Frontiers | Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia - ScienceDirect
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia -
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study | Leukemia
ADVANCES IN TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Ibrutinib Versus FCR: A "Paradigm Shift" for Younger Patients With Treatment-Naïve CLL
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia | NEJM
Treatment Initiation and Selection in Newly Diagnosed CLL - ppt download
Cancers | Free Full-Text | Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL | NEJM
British Journal of Haematology | Wiley Online Library
Ibrutinib and Rituximab (IR) is Superior to Chemo-immunotherapy (CIT) in CLL: Big News, or is it really? And did they get it right? - CLL Society
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia | NEJM
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia | Annals of Hematology
Ongoing or planned phase 3 trials in the first-line setting for CLL | Download Table
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect
